Quantcast

Latest American Association for Cancer Research Stories

2011-11-15 21:15:41

Researchers have developed a new genetic screening tool that will aid in the investigation of possible treatments for patients with melanoma and the unique genetic mutations that may accompany the disease, according to data presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011. Heinz-Herbert Fiebig, M.D., Ph.D., associate professor of medical oncology at the University of Freiburg in Germany, presented data from 25...

2011-11-14 22:26:23

Scientists are another step closer to understanding what drives tumor metastasis, as laboratory models suggest there are factors inside tumors that can slow their own growth. In a recent issue of Cancer Research, a journal of the American Association for Cancer Research, Raúl A. Ruggiero, Ph.D., a biological researcher at the division of experimental medicine at the National Academy of Medicine in Buenos Aires, Argentina, described this novel mechanism. Ruggiero and...

2011-11-14 15:24:49

Findings from preclinical studies in a skin cancer model showed that next-generation BRAF inhibitors used alone, or first-generation BRAF inhibitors used in combination with an epidermal growth factor receptor inhibitor, may have the potential to prevent drug-induced skin lesions in BRAF mutation-positive patients treated for melanoma. The studies, presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011, further elucidated...

2011-11-14 15:21:51

Combining the investigational agents REGN910 and aflibercept yielded statistically significant improvements in antitumor effects in animal models compared with either agent alone, according to results presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011. "These preclinical findings suggest that combining REGN910 (SAR307746) and aflibercept in the clinic could be an attractive approach for future clinical research," said...

2011-11-14 15:20:53

Despite the widespread use of current antiangiogenic cancer therapies, many tumors escape this blockade, which is designed to shut down growth of new blood vessels that feed tumors and spread cancer cells. Now, a study reported at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics suggests that targeting a novel antiangiogenic receptor may help patients whose cancer does not respond to existing agents. The experimental agent, PF-03446962, targets activin...

2011-11-14 15:19:50

Researchers have created a new phenotypic screening platform that better predicts success of drugs developed to prevent blood vessel tumor growth when moving out of the lab and onto actual tumors. "This platform allows us to predict what's going to happen in preclinical models," said Enrique Zudaire, Ph.D., staff scientist in the radiation oncology branch of the National Cancer Institute, who presented the findings at the AACR-NCI-EORTC International Conference: Molecular Targets and...

2011-11-14 11:37:46

Amplification of anaplastic lymphoma kinase, which has been reported in other cancers such as non-small cell lung cancers, may be a primary driver of the rapid metastasis that patients with inflammatory breast cancer experience. If validated, the use of anaplastic lymphoma kinase (ALK) inhibitors may be a new treatment approach for patients with this lethal form of breast cancer. These data were presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer...

2011-11-14 11:36:38

Clinical benefit from use of a novel histone deacetylase inhibitor drug may be determined by examining blood cells days after a patient receives treatment. The drug, entinostat, is the first histone deacetylase inhibitor successfully tested in a randomized, placebo-controlled study in metastatic breast cancer – and is the first to show that clinical outcome can be predicted shortly after administration. The findings, reported at the AACR-NCI-EORTC International Conference: Molecular...

2011-11-09 16:07:51

Patients with recurrent metastatic non-small cell lung cancer have a morbid prognosis, but a new epigenetic therapy may have potential in this population, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research. A research team at Johns Hopkins University tested a combination epigenetic therapy of azacitidine and entinostat among patients with recurrent metastatic non-small cell lung cancer who had been heavily pretreated but showed no...

2011-10-31 13:07:24

Scientists at Dalhousie University in Nova Scotia have identified a key mechanism of metastasis that could lead to blocking tumor growth if their findings are confirmed. In a recent issue of Cancer Research, a journal of the American Association for Cancer Research, lead researcher David Waisman, Ph.D., professor in the Departments of Biochemistry and Molecular Biology and Pathology, and Canada Research Chair in Cancer Research at Dalhousie University, detailed the key role the macrophage...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.